Report Details:
15 Companies Covered
128 Pages
Nasal Mucosa Drug Supply Device Market Highlights
Nasal Mucosa Drug Supply Device Market was estimated at 90.31 USD Billion in 2024. The Nasal Mucosa Drug Supply Device industry is projected to grow from USD 97.0 Billion in 2025 to USD 198.06 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.4% during the forecast period 2025 - 2035
MRFR recognizes the following companies as the key players in the global nasal mucosa drug supply device market GSK plc (UK), AstraZeneca (UK), Pfizer, Inc (US)
Becton, Dickinson, and Company (US), Dr. Reddy's Laboratories (India), Cadila Pharmaceuticals Ltd (India), B.F. Ascher & Company, Inc (US), Douglas Pharmaceuticals Ltd (New Zealand), ENT Technologies Pty. Ltd (Australia), NAVEH Pharma Ltd (Israel) and others.
The single largest growth trend is the increasing prevalence of chronic respiratory disease. The market space witnesses rising research and development activity across the globe which drives the growth of the nasal mucosa drug supply device market. In addition, increasing the new product launches and technological innovation. One such key growth factor promoting an exponential increase in Year on Year (%) growth due to the rising healthcare expenditure is driving the growth of the nasal mucosa drug supply device market.
Furthermore, strategic alliances such as merger acquisition, partnership, and agreement propel the growth of nasal mucosa drug supply device market. However, the high cost of the device is expected to hamper the growth of the global market. Nevertheless, the rising awareness about the nasal mucosa drug supply device is projected to create lucrative opportunity pockets for market players. We estimate a more focused business initiates targeting the same would result in greater revenue pockets for market players.
Segment Analysis
The global nasal mucosa drug supply device market is segmented into type, application, and distribution channel. Based on the type of segment market is further sub segmented into dry powder inhaler, metered dose inhaler, nebulizer. The dry powder inhaler segment was attributed to holding the largest market share in 2022 with a market share of 59.8% of revenue as estimated by MRFR analysts.
The dry powdered inhaler (DPI) is an asthma widely treatment solution for older kids and teens. Utilizing a dry powdered inhaler apportions medicine to get immersed into the lungs. Contrasting other inhalers which deliver a puff of medicine, these inhalers wedge the medicine as a dry powder.
Further, we estimate that the market segment will have a large patient pool suffering from chronic respiratory disease during the forecast period. It has been identified that the segment market yet witnesses continuous new product development and a growing number of product approvals. For instance, in July 2019, Eli Lilly and Company received FDA approval for its BAQSIMI (glucagon) nasal powder of 3 mg to treat severe hypoglycemia in patients with diabetes ages four years and above. Eli Lilly and Company announced that BAQSIMI is the first and only nasally administered glucagon, developed for severe hypoglycemia patients.
Further, based on application, the market is segmented into asthma, chronic obstructive pulmonary disease, and others. Distribution channels are further sub segmented into hospital pharmacies, retail pharmacies and online pharmacies.
Regional Analysis
The global nasal mucosa drug supply device market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World.
The nasal mucosa drug supply device market for North America is analyzed across US and Canada. US accounted for a major share of the nasal mucosa drug supply device market in 2022 and is expected to maintain its lead during the forecast period, due to the rising incidence of respiratory disease, increasing demand of nasal mucosa drug delivery system, business headquarter of major key players. For instance: Pfizer, Inc (US), OptiNose, Inc (US), Becton, Dickinson, and Company (US), Promius Pharma, LLC (US), and many other major key players having their business presence in the North America region which is driving the growth of nasal mucosa drug supply device market in the North America region.
Moreover, the Europe market has been persistently growing owing to factors such as the increasing technological development and product innovation, rising research and development activity, highly investment by the major players for expanding their business in the region as well as government initiatives for the reducing risk of asthma across the region propel the growth of nasal drug supply delivery device market in the Europe market is driving the Europe nasal mucosa drug supply device market.
Additionally, market factors, such as an increasing healthcare expenditure, rising geriatric population, increasing strategic alliance such as expansion, merger, acquisition, supply, and distribution agreement which further drive the growth of nasal mucosa drug supply device market in the Asia-Pacific region.
Furthermore, the rest of the world's market is divided into the Middle East, Africa, and Latin America. The market factors such as an increasing awareness about the nasal drug delivery devices, rising medical facility, availability of better medical staff across the region are boosting the growth of nasal mucosal drug delivery devices in region.
Key Findings of the Study
-
- Technological advancements are enhancing the efficacy and usability of nasal drug delivery devices.
- North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region in this sector.
- The Metered Dose Inhaler segment dominates the market, whereas the Dry Powder Inhaler segment is witnessing rapid growth.
- Rising prevalence of respiratory disorders and growing demand for non-invasive treatment options are key drivers propelling market expansion.
